The lipid-lowering effect of ezetimibe in pure vegetarians

Jacob J. Clarenbach, Michael Reber, Dieter Lütjohann, Klaus Von Bergmann, Thomas Sudhop

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200-500 mg/day) by 16-22%. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied. We conducted a randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2 week washout period. Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method. Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2% and was decreased by 58% during ezetimibe treatment to 20.2 ± 6.2% (P < 0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3%. In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/day) leads to a significant reduction of cholesterol absorption and a clinically relevant decrease of plasma LDL cholesterol, comparable to that of subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.

Original languageEnglish (US)
Pages (from-to)2820-2824
Number of pages5
JournalJournal of Lipid Research
Volume47
Issue number12
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Dietary Cholesterol
Cholesterol
Lipids
LDL Cholesterol
Placebos
Feeding Methods
Plasmas
Intestinal Absorption
Nutrition
Vegetarians
Ezetimibe
Hypercholesterolemia
Isotopes
Cross-Over Studies
Therapeutics
Diet

Keywords

  • Campesterol
  • Cholesterol absorption
  • Cholesterol synthesis
  • Lathosterol
  • Sitosterol

ASJC Scopus subject areas

  • Endocrinology

Cite this

The lipid-lowering effect of ezetimibe in pure vegetarians. / Clarenbach, Jacob J.; Reber, Michael; Lütjohann, Dieter; Von Bergmann, Klaus; Sudhop, Thomas.

In: Journal of Lipid Research, Vol. 47, No. 12, 12.2006, p. 2820-2824.

Research output: Contribution to journalArticle

Clarenbach, JJ, Reber, M, Lütjohann, D, Von Bergmann, K & Sudhop, T 2006, 'The lipid-lowering effect of ezetimibe in pure vegetarians', Journal of Lipid Research, vol. 47, no. 12, pp. 2820-2824. https://doi.org/10.1194/jlr.P600009-JLR200
Clarenbach, Jacob J. ; Reber, Michael ; Lütjohann, Dieter ; Von Bergmann, Klaus ; Sudhop, Thomas. / The lipid-lowering effect of ezetimibe in pure vegetarians. In: Journal of Lipid Research. 2006 ; Vol. 47, No. 12. pp. 2820-2824.
@article{6d530a7666bc42b4942965e1db4d2ce0,
title = "The lipid-lowering effect of ezetimibe in pure vegetarians",
abstract = "Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200-500 mg/day) by 16-22{\%}. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied. We conducted a randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2 week washout period. Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method. Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2{\%} and was decreased by 58{\%} during ezetimibe treatment to 20.2 ± 6.2{\%} (P < 0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3{\%}. In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/day) leads to a significant reduction of cholesterol absorption and a clinically relevant decrease of plasma LDL cholesterol, comparable to that of subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.",
keywords = "Campesterol, Cholesterol absorption, Cholesterol synthesis, Lathosterol, Sitosterol",
author = "Clarenbach, {Jacob J.} and Michael Reber and Dieter L{\"u}tjohann and {Von Bergmann}, Klaus and Thomas Sudhop",
year = "2006",
month = "12",
doi = "10.1194/jlr.P600009-JLR200",
language = "English (US)",
volume = "47",
pages = "2820--2824",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - The lipid-lowering effect of ezetimibe in pure vegetarians

AU - Clarenbach, Jacob J.

AU - Reber, Michael

AU - Lütjohann, Dieter

AU - Von Bergmann, Klaus

AU - Sudhop, Thomas

PY - 2006/12

Y1 - 2006/12

N2 - Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200-500 mg/day) by 16-22%. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied. We conducted a randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2 week washout period. Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method. Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2% and was decreased by 58% during ezetimibe treatment to 20.2 ± 6.2% (P < 0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3%. In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/day) leads to a significant reduction of cholesterol absorption and a clinically relevant decrease of plasma LDL cholesterol, comparable to that of subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.

AB - Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200-500 mg/day) by 16-22%. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied. We conducted a randomized, double-blind, placebo-controlled, two-phase crossover study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2 week washout period. Fractional cholesterol absorption was determined using the continuous dual stable isotope feeding method. Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during the placebo phase was 48.2 ± 8.2% and was decreased by 58% during ezetimibe treatment to 20.2 ± 6.2% (P < 0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol of 17.3%. In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/day) leads to a significant reduction of cholesterol absorption and a clinically relevant decrease of plasma LDL cholesterol, comparable to that of subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.

KW - Campesterol

KW - Cholesterol absorption

KW - Cholesterol synthesis

KW - Lathosterol

KW - Sitosterol

UR - http://www.scopus.com/inward/record.url?scp=33845578757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845578757&partnerID=8YFLogxK

U2 - 10.1194/jlr.P600009-JLR200

DO - 10.1194/jlr.P600009-JLR200

M3 - Article

VL - 47

SP - 2820

EP - 2824

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 12

ER -